Comparison of N-glycans expressed in tumor tissues with those expressed in adjacent non-tumor tissues of colorectal cancer patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Ji, Eunhee | - |
dc.date.available | 2020-02-27T03:41:21Z | - |
dc.date.created | 2020-02-04 | - |
dc.date.issued | 2019-05 | - |
dc.identifier.issn | 0946-1965 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/1509 | - |
dc.description.abstract | Background: The associations between colorectal cancer (CRC) progression and changes in N-glycan expression suggest the potential for new biomarkers and targeted cancer therapies. This study was performed to analyze N-glycans and to compare their expression profiles in tumor and corresponding adjacent non-tumor (control) tissues in stage I and IV CRC patients to examine N-glycans as potential prognostic markers. Materials and methods: Six adult CRC patients, including 3 in stage I and 3 in stage IV who underwent curative surgery were enrolled in this study. The tumor and control tissue samples were collected during surgery. Tissue samples were analyzed using liquid chromatography-tandem mass spectrometry as well as database searching. Results: In this study, 76 N-glycans from 12 tissues of 6 CRC patients were profiled. There were 6 high mannose, 3 mannose, 1 core, 14 hybrid, 30 hybrid/complex, and 22 complex type N-glycans. There were 44 N-glycans in stage I control, 29 in stage I tumor, 43 in stage IV control, and 54 in stage IV tumor. Tumor-and stage-specific N-glycans were also identified. The relative abundance of N-glycans varied across the divided group. Conclusion: N-glycans presented only in stage I tumor from the biopsy sample for the diagnosis of CRC or in stage I control obtained during the surgery showed potential as biomarkers to predict CRC prognosis. Further high-throughput glycomic study should be performed with a larger sample size. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | DUSTRI-VERLAG DR KARL FEISTLE | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | - |
dc.subject | CELL-LINES | - |
dc.subject | GLYCOSYLATION | - |
dc.subject | BIOMARKERS | - |
dc.title | Comparison of N-glycans expressed in tumor tissues with those expressed in adjacent non-tumor tissues of colorectal cancer patients | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000464419200003 | - |
dc.identifier.doi | 10.5414/CP203332 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, v.57, no.5, pp.249 - 258 | - |
dc.identifier.scopusid | 2-s2.0-85064853296 | - |
dc.citation.endPage | 258 | - |
dc.citation.startPage | 249 | - |
dc.citation.title | INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS | - |
dc.citation.volume | 57 | - |
dc.citation.number | 5 | - |
dc.contributor.affiliatedAuthor | Ji, Eunhee | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | colorectal cancer | - |
dc.subject.keywordAuthor | N-glycan profiling | - |
dc.subject.keywordAuthor | glycosylation | - |
dc.subject.keywordAuthor | LC-MS/MS spectrometry | - |
dc.subject.keywordPlus | CELL-LINES | - |
dc.subject.keywordPlus | GLYCOSYLATION | - |
dc.subject.keywordPlus | BIOMARKERS | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.